Immunosuppression and KT characteristics of the six patients converted to belatacept
| A: Immunosuppression and KT characteristics of the 6 patients converted to belatacept | ||||||
| Patient # | Induction therapy | Maintenance drugs | Time from KT to belatacept | Meds when starting belatacept | EBV | Time on belatacept |
| A | Thymoglobuline | MMF 2160, TAC 8, NO PRED | 30 months | MMF 1440, TAC 8, PRED 10 | + | 1 month |
| B | Basiliximab | MMF 1440, CYC 300, PRED 10 | 4 months | MMF 500, CYC 150, PRED 5 | + | 37 months |
| C | Thymoglobuline | MPA 640, TAC 10, PRED 5 | 3.5 months | MPA 360, TAC 10, PRED 5 | + | 48 months |
| D | Thymoglobuline | MMF 1440, TAC 10, PRED 10 | 38 months | TAC 6, AZA 25, PRED 5 | + | 13 months |
| E | Thymoglobuline | MMF 2000, TAC 10, PRED 5 | 3.5 months | MMF 2000, TAC 8, PRED 10 | + | 37 months |
| F | Alemtuzumab | MMF 1140, TAC 10, PRED 10 | 0.75 months | MPA 1440, TAC 8, PRED 5 | + | 31 months |
| B: Immunosuppression and KT characteristics of the 6 patients converted to belatacept | ||||||
| Patient # | Reason for belatacept switch | DGF | Donor age | Cold isquemia time | RT failure | Last PC ratio |
| A | Non-adherence | No | 33 years | 40 hours | ACR, BK nephropathy | 0.32 |
| B | Cortical necrosis | Yes | 25 years | 42 hours 10 min | ACR, cortical necrosis | 1.49 |
| C | CNI side effects | No | 0.06 | |||
| D | CNI side effects | No | CNI, pyelonephritis, recurrent LN | |||
| E | CNI side effects | No | 45 years | 4 hours 02 min | ACR | 0.44 |
| F | TMA on biopsy | Yes | 44 years | 41 hours | ACR, TMA | 0.125 |
#, number; ACR, acute cellular rejection;AZA, azathioprine; BK, BK virus; CNI, calcineurin inhibitors; CYC, cyclosporine; DGF, delayed graft function;EBV, Epstein Barr Virus; KT, kidney transplant; LN, lupus nephritis;meds, medications; min, minutes;MMF, mycophenolate mofetil; MPA, mycophenolic acid; PRED, prednisone; PCR Ratio, random urine protein creatinine ratio; RT, renal transplant;TAC, tacrolimus; TMA, thrombotic microangiopathy.